<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302041</url>
  </required_header>
  <id_info>
    <org_study_id>9785-CL-0321</org_study_id>
    <secondary_id>2010-021287-16</secondary_id>
    <nct_id>NCT01302041</nct_id>
  </id_info>
  <brief_title>A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy</brief_title>
  <official_title>A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naïve Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with
      prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2011</start_date>
  <completion_date type="Actual">April 27, 2017</completion_date>
  <primary_completion_date type="Actual">July 29, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Prostate-specific Antigen (PSA) Response at Week 25</measure>
    <time_frame>Baseline and Week 25</time_frame>
    <description>A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory.
Participants with an unknown or missing response or who discontinued prior to Week 25 for any reason were treated as non-responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From first dose of study drug until 30 days after last dose. Adverse events with an onset date occurring within 2 years (i.e., before or on Day 730), as of the cut-off date of 28 December 2013, are reported.</time_frame>
    <description>Each adverse events (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs).
A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose:
Resulted in death
Was life-threatening
Resulted in persistent or significant disability/incapacity
Resulted in congenital anomaly or birth defect
Required inpatient hospitalization or led to prolongation of hospitalization
Other medically important events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PSA</measure>
    <time_frame>Baseline and Weeks 25, 49 and 97</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Sex Hormone-binding Globulin (SHBG)</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Androstenedione</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Dehydroepiandrosterone (DHEA)</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Dihydrotestosterone (DHT)</measure>
    <time_frame>Baseline and Week 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Estradiol</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Follicle-stimulating Hormone (FSH)</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Luteinizing Hormone (LH)</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Prolactin</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Testosterone</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Free Testosterone</measure>
    <time_frame>Baseline and Weeks 25 and 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Enzalutamide at Pre-dose (Ctrough)</measure>
    <time_frame>Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)</measure>
    <time_frame>Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a PSA Response at Weeks 49 and 97</measure>
    <time_frame>Baseline and Weeks 49 and 97</time_frame>
    <description>A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to Week 49 or Week 97 for any reason were treated as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level</measure>
    <time_frame>Baseline and Weeks 25, 49 and 97</time_frame>
    <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PSA ≤ 4 ng/ml</measure>
    <time_frame>Weeks 25, 49 and 97</time_frame>
    <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PSA ≤ 0.1 ng/ml</measure>
    <time_frame>Weeks 25, 49 and 97</time_frame>
    <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Decline From Baseline in PSA</measure>
    <time_frame>Baseline to Week 25 and from Baseline up to the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929)</time_frame>
    <description>The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to Week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Response</measure>
    <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days)</time_frame>
    <description>Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Decline ≥ 90%</measure>
    <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days)</time_frame>
    <description>Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA ≤ 4 ng/ml</measure>
    <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days).</time_frame>
    <description>Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA ≤ 0.1 ng/ml</measure>
    <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days).</time_frame>
    <description>Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded.
Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days).</time_frame>
    <description>Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Doubling Time</measure>
    <time_frame>From Baseline to Week 25</time_frame>
    <description>PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Oral</description>
    <arm_group_label>Enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
    <other_name>MDV3100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate cancer (all stages) for whom androgen deprivation
             therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy)

          -  Asymptomatic from prostate cancer

          -  Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening

          -  PSA ≥ 2 ng/mL at screening

        Exclusion Criteria:

        Has previously or is currently receiving:

          -  Hormonal therapy with intent to treat prostate cancer

          -  Systemic glucocorticoids

          -  Chemotherapy with the intent to treat prostate cancer

          -  Opiate analgesics for pain from prostate cancer

          -  Radiation therapy for treatment of the primary tumor or metastases

          -  Has history of known or suspected brain or skull metastases or leptomeningeal disease

          -  Has history of seizure including febrile seizure or any condition that may predispose
             to seizure or history of loss of consciousness or transient ischemic attack

          -  Clinically significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site BE1003</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE1001</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE1002</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE1005</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ3006</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ3002</name>
      <address>
        <city>Praha 6</city>
        <zip>16000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK4001</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK4004</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK4002</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE5005</name>
      <address>
        <city>Aachen</city>
        <zip>51074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE5007</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE5003</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=44</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>February 16, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2016</results_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone turnover</keyword>
  <keyword>hormone-naïve</keyword>
  <keyword>prostate specific antigen</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study is ongoing, data are reported as of the 2 year cut-off date of 28 December 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Enzalutamide</title>
          <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17">Participants who discontinued treatment and completed the 30-day follow-up visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Continuing on Study</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Miscellaneous Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enzalutamide</title>
          <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.0" spread="7.66" lower_limit="48" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.17" spread="3.408" lower_limit="20.8" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.2" spread="102.990" lower_limit="6.4" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of prostate cancer</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Gleason Score at Initial Diagnosis</title>
          <description>A system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Tumor Stage (T) at Initial Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TX: Primary tumor cannot be assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T0: No evidence of primary tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Tumor neither palpable or visible by imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Tumor confined within the prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Tumor extends through the prostatic capsule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Tumor is fixed or invades adjacent structures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Lymph Node Stage (N) at Initial Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NX: Regional lymph nodes were not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N0: No regional lymph node metastasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1: Metastasis in regional lymph node(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distant Metastasis (M) at Initial Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>MX: Distant metastasis could not be assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M0: No distant metastasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1: Distant metastasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Metastases at Study Entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Metastatic Lesions by Bone Scan</title>
          <units>lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Interventions</title>
          <description>Participants may have received more than one intervention</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostatectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transurethral resection of the prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic lymph node dissection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watchful waiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other surgeries/procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Prostate-specific Antigen (PSA) Response at Week 25</title>
        <description>A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory.
Participants with an unknown or missing response or who discontinued prior to Week 25 for any reason were treated as non-responders.</description>
        <time_frame>Baseline and Week 25</time_frame>
        <population>Safety Analysis Set (all participants who had taken at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Prostate-specific Antigen (PSA) Response at Week 25</title>
          <description>A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory.
Participants with an unknown or missing response or who discontinued prior to Week 25 for any reason were treated as non-responders.</description>
          <population>Safety Analysis Set (all participants who had taken at least 1 dose of study drug)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="83.44" upper_limit="97.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Each adverse events (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs).
A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose:
Resulted in death
Was life-threatening
Resulted in persistent or significant disability/incapacity
Resulted in congenital anomaly or birth defect
Required inpatient hospitalization or led to prolongation of hospitalization
Other medically important events.</description>
        <time_frame>From first dose of study drug until 30 days after last dose. Adverse events with an onset date occurring within 2 years (i.e., before or on Day 730), as of the cut-off date of 28 December 2013, are reported.</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Each adverse events (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs).
A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose:
Resulted in death
Was life-threatening
Resulted in persistent or significant disability/incapacity
Resulted in congenital anomaly or birth defect
Required inpatient hospitalization or led to prolongation of hospitalization
Other medically important events.</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug regimen related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug regimen related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DRRAEs leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in PSA</title>
        <time_frame>Baseline and Weeks 25, 49 and 97</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in PSA</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.82" spread="5.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98.96" spread="2.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97 (N=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-99.44" spread="1.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Sex Hormone-binding Globulin (SHBG)</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Sex Hormone-binding Globulin (SHBG)</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.60" spread="49.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.45" spread="41.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Androstenedione</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Androstenedione</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.06" spread="59.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.94" spread="55.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Dehydroepiandrosterone (DHEA)</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Dehydroepiandrosterone (DHEA)</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.59" spread="58.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" spread="54.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Dihydrotestosterone (DHT)</title>
        <time_frame>Baseline and Week 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Dihydrotestosterone (DHT)</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.72" spread="57.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.35" spread="101.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Estradiol</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Estradiol</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.69" spread="73.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.00" spread="82.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Follicle-stimulating Hormone (FSH)</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Follicle-stimulating Hormone (FSH)</title>
          <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.99" spread="46.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.18" spread="78.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Luteinizing Hormone (LH)</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Luteinizing Hormone (LH)</title>
          <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.66" spread="120.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.18" spread="163.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Prolactin</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Prolactin</title>
          <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.79" spread="45.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N-53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" spread="30.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Testosterone</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Testosterone</title>
          <population>Safety Analysis Set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.29" spread="73.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.73" spread="76.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Free Testosterone</title>
        <time_frame>Baseline and Weeks 25 and 49</time_frame>
        <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Free Testosterone</title>
          <population>Safety Analysis Set with available data at each time point (Indicated by &quot;N&quot;)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.39" spread="59.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.74" spread="55.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Enzalutamide at Pre-dose (Ctrough)</title>
        <time_frame>Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25</time_frame>
        <population>Pharmacokinetic Analysis Set (participants who had taken at least 1 dose of study drug and who had at least 1 pharmacokinetic concentration value) with available data at each time point (indicated by &quot;N&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Enzalutamide at Pre-dose (Ctrough)</title>
          <population>Pharmacokinetic Analysis Set (participants who had taken at least 1 dose of study drug and who had at least 1 pharmacokinetic concentration value) with available data at each time point (indicated by &quot;N&quot;).</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.225" spread="1.8050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (N=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.559" spread="2.1967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.838" spread="2.4605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (N=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.161" spread="2.8496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.606" spread="3.0084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.868" spread="2.9760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21 (N=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.224" spread="2.8899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.668" spread="2.7624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)</title>
        <time_frame>Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25</time_frame>
        <population>Pharmacokinetic Analysis Set with available data at each time point (indicated by &quot;N&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)</title>
          <population>Pharmacokinetic Analysis Set with available data at each time point (indicated by &quot;N&quot;).</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.527" spread="1.0440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (N=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.344" spread="1.7079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.182" spread="2.4366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (N=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.962" spread="2.7584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.128" spread="3.1262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.780" spread="3.2564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21 (N=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.717" spread="2.9502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 (N=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.146" spread="2.5845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a PSA Response at Weeks 49 and 97</title>
        <description>A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to Week 49 or Week 97 for any reason were treated as non-responders.</description>
        <time_frame>Baseline and Weeks 49 and 97</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a PSA Response at Weeks 49 and 97</title>
          <description>A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to Week 49 or Week 97 for any reason were treated as non-responders.</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" lower_limit="69.11" upper_limit="89.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="54.60" upper_limit="78.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level</title>
        <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
        <time_frame>Baseline and Weeks 25, 49 and 97</time_frame>
        <population>Safety Analysis Set; Week 49 and 97 analyses include participants who were on study at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level</title>
          <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
          <population>Safety Analysis Set; Week 49 and 97 analyses include participants who were on study at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97 (N=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PSA ≤ 4 ng/ml</title>
        <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
        <time_frame>Weeks 25, 49 and 97</time_frame>
        <population>Safety Analysis Set; Week 49 and 97 analyses include participants who were on study at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PSA ≤ 4 ng/ml</title>
          <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
          <population>Safety Analysis Set; Week 49 and 97 analyses include participants who were on study at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97 (N=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PSA ≤ 0.1 ng/ml</title>
        <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
        <time_frame>Weeks 25, 49 and 97</time_frame>
        <population>Safety Analysis Set; Week 49 and 97 analyses include participants who were on study at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PSA ≤ 0.1 ng/ml</title>
          <description>Participants with unknown or missing PSA results at Week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25.
Participants with unknown or missing PSA results at Week 49 or Week 97 were considered non-responders.</description>
          <population>Safety Analysis Set; Week 49 and 97 analyses include participants who were on study at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 25 (N=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 (N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97 (N=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Decline From Baseline in PSA</title>
        <description>The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to Week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.</description>
        <time_frame>Baseline to Week 25 and from Baseline up to the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Decline From Baseline in PSA</title>
          <description>The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to Week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum Decline by Data Cut-off Date</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-99.05" spread="2.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Decline by Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98.32" spread="2.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Response</title>
        <description>Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.</description>
        <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Response</title>
          <description>Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.</description>
          <population>Safety Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="28" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Decline ≥ 90%</title>
        <description>Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.</description>
        <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Decline ≥ 90%</title>
          <description>Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.</description>
          <population>Safety Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="29" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA ≤ 4 ng/ml</title>
        <description>Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.</description>
        <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days).</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA ≤ 4 ng/ml</title>
          <description>Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.</description>
          <population>Safety Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="9" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA ≤ 0.1 ng/ml</title>
        <description>Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded.
Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.</description>
        <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days).</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA ≤ 0.1 ng/ml</title>
          <description>Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded.
Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.</description>
          <population>Safety Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="58" upper_limit="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression</title>
        <description>Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.</description>
        <time_frame>From first dose until the data cut-off date of 28 December 2013; median duration of treatment was 754.0 days (range of 52-929 days).</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <description>Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.</description>
          <population>Safety Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Could not be estimated due to the low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Doubling Time</title>
        <description>PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.</description>
        <time_frame>From Baseline to Week 25</time_frame>
        <population>Safety Analysis Set with a positive PSA versus time slope</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide</title>
            <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Doubling Time</title>
          <description>PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.</description>
          <population>Safety Analysis Set with a positive PSA versus time slope</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug until 30 days after last dose. Adverse events with an onset date occurring within 2 years (i.e., before or on Day 730), as of the cut-off date of 28 December 2013, are reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enzalutamide</title>
          <description>Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic fatigue syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Seizure anoxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site. Sponsor must receive a site’s manuscript at least 90 days prior to publication for review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Astellas Pharma Global Devlopment, Inc.</organization>
      <email>Astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

